BRAF and colorectal cancer: Our data suggest that, while VE-1 may represent a specific tool for detecting BRAF V600E mutations in validated tumors, such as melanoma or colorectal cancer metastases, it is unsuitable for detecting potential BRAF V600E mutations in breast cancer, lung adenocarcinomas and pituitary adenomas, further supporting that the specificity of VE-1 should be thoroughly examined for each tumor entity by paralleled genetic mutation analysis prior to routine application for research or diagnostics.